Corgenix's lupus diagnostic:
This article was originally published in Clinica
Corgenix Medical has received US 510(k) clearance of its IgG Anti-AtherOx test kit. It will be used in patients with systemic lupus erythematosus (SLE) and lupus-like disorders such as antiphospholipid syndrome, to assess their risk of vascular injuries or thrombosis. The test is already CE marked for use in the EU, and Denver, Colorado-based Corgenix said that it is now available worldwide. Studies have shown that measurement of the AtherOx antibody was significantly better than conventional anti-cardiolipin testing, the firm said.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.